Indivior Pharmaceuticals Inc

NASDAQ:INDV

Drug Manufacturers - Specialty & Generic

Healthcare
$36.28 +0.69%

+$0.26 today

Market cap
$4.53B
Beta
1.17
P/E (TTM)
19.1
EPS (TTM)
$2.00
52W Low $13.45High $41.00

Volume 3.65M

Average 2.08M

INDV Income Before Tax

Profit after all operating and non-operating items but before income tax.

Indivior Pharmaceuticals IncNASDAQ: INDV

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax growth accelerates

Q2 FY2026 income before tax of $160M rose 158.1% year over year, ahead of the +88.9% change in trailing-twelve-month income before tax. Sequentially, it rose 39.1% from the prior quarter.

Context

  • Income before tax amounted to 19.3% of revenue in FY2025, up 18.1 pp from a year earlier.
  • Income before tax increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +158.1% holds above the trailing-twelve-month pace of +88.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$160M+39.1% QoQ
Last fiscal yearDec 2025
$239M+1607.1% YoY
LTMJun 2026
$393M+88.9% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+158.1%——
1 year+1607.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
239M USD
Year-over-year change
+1607.1%
4-year CAGR
+5.9%

Income Before Tax vs competitors

How INDV compares with its peers on the latest reported figures

  • INDV's LTM Jun 2026 income before tax of $393M is the highest of the 4 companies compared; the peer median is $11.31M.
  • Its year-over-year change of +88.9% is the highest of 4, against a peer median of -97.2%.
  • Income before tax amounts to 29.5% of revenue for INDV, versus a peer median of 13.6%.
INDV Competitors Peer median
Income Before Tax for INDV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INDVIndivior Pharmaceuticals IncLTM Jun 2026$393M +88.9%—29.5%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$108.24M +66.3%—13.6%
ALKSAlkermes plcLTM Sep 2026$11.31M -97.2%—0.6%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-$123.47M -250.3%—14.9%
Peer median (excluding INDV) $11.31M-97.2%—13.6%

Competitors are the stored peer set for INDV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue791M901M1.09B1.19B1.24B
Cost of Revenue127M151M174M231M246M
Gross Profit664M750M919M957M993M
Gross Margin83.9%83.2%84.1%80.6%80.1%
Research & Development52M74M116M107M97M
Selling, General & Admin431M469M569M618M634M
Operating Expenses451M831M1.08B925M728M
Depreciation & Amortization22M16M15M28M20M
EBITDA238M(46M)(99M)83M304M
EBITDA Margin30.1%-5.1%-9.1%7.0%24.5%
Operating Income213M(81M)(156M)32M265M
Operating Margin26.9%-9.0%-14.3%2.7%21.4%
Interest Income4M19M43M23M22M
Interest Expense26M29M35M41M45M
Other Income / Expenses(23M)(8M)7M(18M)(26M)
Income Before Tax190M(89M)(149M)14M239M
Pre-Tax Margin24.0%-9.9%-13.6%1.2%19.3%
Income Tax Expense(15M)(44M)(20M)11M29M
Net Income205M(44M)(129M)2M210M
Net Margin25.9%-4.9%-11.8%0.2%16.9%
EPS (Basic)1.38(0.37)(0.94)0.021.68
EPS (Diluted)1.31(0.37)(0.91)0.021.64
Weighted Avg Shares145.66M139.01M137.31M132M125M
Weighted Avg Shares (Diluted)154.23M139.01M141.8M133M128M

Indivior Pharmaceuticals Inc

NASDAQ:INDV

Intrinsic Alpha fair value

Locked

Current Price

$36.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.